Detection of Plasma BRAFV600E Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The BRAFV600E mutation represents a novel indicator of the progression and aggressiveness of papillary thyroid carcinoma (PTC). The purpose of this study was to determine the clinical significance of free circulating mutant BRAFV600E in predicting the advanced disease of PTC. Materials and Methods: Seventy seven matched tumor and plasma samples obtained from patients with both benign and PTC were analyzed for BRAFV600E mutation using a peptide nucleic acid (PNA) clamp real-time polymerase chain reaction (PCR). Results: The BRAFV600E mutationwas absent in tumor DNA samples obtained from patients with benign follicularadenomas or adenomatous goiter. In contrast, 49 of 72 (68.1%) PTC tumors were positive for the BRAFV600E mutation. Among them, 3 (6.1%) patients with PTC were positive for BRAFV600E mutation in plasma and tumor. However, all 3 patients(100%) had lateral lymph node and lung metastasis. Conclusion: These findingssuggest that the BRAFV600E mutation can be detected using a PNA clamp real-time PCR in the blood of PTC patients with lung metastasis. Future studies are warranted to determine clinical significance of serum BRAFV600E mutation in large prospective studies.
Abstract
Purpose: The BRAFV600E mutation represents a novel indicator of the progression and aggressiveness of papillary thyroid carcinoma (PTC). The purpose of this study was to determine the clinical significance of free circulating mutant BRAFV600E in predicting the advanced disease of PTC. Materials and Methods: Seventy seven matched tumor and plasma samples obtained from patients with both benign and PTC were analyzed for BRAFV600E mutation using a peptide nucleic acid (PNA) clamp real-time polymerase chain reaction (PCR). Results: The BRAFV600E mutationwas absent in tumor DNA samples obtained from patients with benign follicularadenomas or adenomatous goiter. In contrast, 49 of 72 (68.1%) PTC tumors were positive for the BRAFV600E mutation. Among them, 3 (6.1%) patients with PTC were positive for BRAFV600E mutation in plasma and tumor. However, all 3 patients(100%) had lateral lymph node and lung metastasis. Conclusion: These findingssuggest that the BRAFV600E mutation can be detected using a PNA clamp real-time PCR in the blood of PTC patients with lung metastasis. Future studies are warranted to determine clinical significance of serum BRAFV600E mutation in large prospective studies.
참고문헌 (28)
- Mazzaferri EL, "Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy", Endocr Pract, 6, pp.469~476 (2000)
- Grebe SK, "Thyroid cancer nodal metastases: biologic significance and therapeutic considerations", Surg Oncol Clin N Am, 5, pp.43~63 (1996)
- Machens A, "Pattern of nodal metastasis for primary and reoperative thyroid cancer", World J Surg, 26, pp.22~28 (2002)
- Stulak JM, "Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer", Arch Surg, 141, pp.489~494 (2006)
- Shaha AR, "Distant metastases from thyroid and parathyroid cancer", ORL J Otorhinolaryngol Relat Spec, 63, pp.243~249 (2001)
- Benbassat CA, "Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer", World J Surg, 30, pp.1088~1095 (2006)
- Liu D, "BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells", J Clin Endocrinol Metab, 92, pp.2264~2271 (2007)
- Cradic KW, "Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status", J Clin Endocrinol Metab, 94, pp.5001~5009 (2009)
- Chuang TC, "Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas", Head Neck, 32, pp.229~234 (2010)
- 김경희, "Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population", Yonsei Medical Journal, 45(5), pp.818~821 (2004), 연세대학교의과대학
- Kim TY, "The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma", Clin Endocrinol (Oxf), 65, pp.364~368 (2006)
- Jeong D, "BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR", Ann Surg Oncol, 20, pp.759~766 (2013)
- Kwon MJ, "Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue", Pathol Res Pract, 207, pp.762~768 (2011)
- Zaydfudim V, "The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma", Surgery, 144, pp.1070~1077 (2008)
- Mazzaferri EL, "Management of a solitary thyroid nodule", N Engl J Med, 328, pp.553~559 (1993)
- Riesco-Eizaguirre G, "The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+", I- targeting to the membrane, 2006, pp.13, 257~269
- Elisei R, "BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study", J Clin Endocrinol Metab, 93, pp.3943~3949 (2008)
- Lupi C, "Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma", J Clin Endocrinol Metab, 92, pp.4085~4090 (2007)
- Lee JH, "Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis", Cancer, 110, pp.38~46 (2007)
- Kebebew E, "The prevalence and prognostic value of BRAF mutation in thyroid cancer", Ann Surg, 246, pp.466~470 (2007)
- Trovisco V, "Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma", Clin Endocrinol (Oxf), 69, pp.683~685 (2008)
- Xing M, "BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications", Endocr Rev, 28, pp.742~762 (2007)
- Guan H, "Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer", J Clin Endocrinol Metab, 94, pp.1612~1617 (2009)
- Kim JY, "Dietary iodine intake and urinary iodine excretion in normal Korean adults", Yonsei Med J, 39, pp.355~362 (1998)
- Kang SH, "Detection of BRAF V600E mutation with thyroid tissue using pyrosequencing: comparison with PNA-clamping and real-time PCR", Am J Clin Pathol, 139, pp.759~764 (2013)
- Kim TY, "The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma", Clin Endocrinol (Oxf), 63, pp.588~593 (2005)
- 나소영, "갑상선 유두암에서의 BRAF 변이와 예후인자와의 관계", Endocrinology and Metabolism, 20(3), pp.224~229 (2005), 대한내분비학회
- Trovisco V, "Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness", Virchows Arch, 446, pp.589~595 (2005)